Vaccines: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
[https://www.nature.com/articles/d41586-025-02439-4 by Smriti Mallapaty 1/8/25 nature] | [https://www.nature.com/articles/d41586-025-02439-4 by Smriti Mallapaty 1/8/25 nature] | ||
The trial is only the third to test mRNA vaccines against HIV. “These are the first studies, so they’re very, very important,” says infectious-disease physician Sharon Lewin, who heads the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia. | The trial is only the third to test mRNA vaccines against HIV. “These are the first studies, so they’re very, very important,” says infectious-disease physician Sharon Lewin, who heads the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia. | ||
=====Addressing the Cold Reality of mRNA Vaccine Stability===== | |||
[https://www.sciencedirect.com/science/article/pii/S0022354920307851 by Daan J.A. Crommelin 3/21 ScienceDirect] | |||
As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain. | |||
Revision as of 09:25, 8 August 2025
Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy
by Umm E. LailaUmm E. LailaWang AnWang AnZhi-Xiang Xu Zhi-Xiang Xu 24/11/2024 Frontiers
Cancer remains a significant global health challenge, with estimates projecting 34 million new cases by 2070 (1). Despite advancements in treatment, current therapies exhibit limitations, emphasizing the need for innovative solutions for cancer treatment. (2). The concept of mRNA cancer vaccines has emerged as a promising avenue for immunotherapy, following the success of mRNA technology in producing effective COVID-19 vaccines during the pandemic. (3–6). Immunotherapy, such as immune checkpoint inhibitors and CAR-T therapies, have revolutionized cancer treatment by harnessing the power of the immune system. (7). Recently, these approaches, combined with mRNA vaccines, offer a personalized and effective strategy against cancer, providing a more targeted approach
mRNA vaccines for HIV trigger strong immune response in people
by Smriti Mallapaty 1/8/25 nature
The trial is only the third to test mRNA vaccines against HIV. “These are the first studies, so they’re very, very important,” says infectious-disease physician Sharon Lewin, who heads the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia.
Addressing the Cold Reality of mRNA Vaccine Stability
by Daan J.A. Crommelin 3/21 ScienceDirect
As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain.
